An innovative cancer-killing virus shows promise for tackling glioblastoma, an aggressive type of brain tumour, according to new results from a phase I clinical trial co-led by researchers at Barts Cancer Institute.
Researchers from Barts Cancer Institute, Queen Mary University of London are part of a nationwide team of universities, hospitals and industry collaborating on a new platform to understand immunotherapy response and side effects in cancer.
An innovative therapy provides new hope to patients with malignant mesothelioma – a rare but rapidly fatal type of cancer with few effective treatment options – according to results presented by Professor Peter Szlosarek and his team at Barts Cancer Institute, Queen Mary University of London.